NanosonicsNNCSF 90 EBITDA Margin % is 15.09% as of Dec. 2025, which is 4% below its 10-year median of 15.73. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.57 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Nanosonics ranks better than 66.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nanosonics's EBITDA for the
six
months ended in Dec. 2025 was $10.3 Mil. Nanosonics's Revenue for the
six
months ended in Dec. 2025 was $67.9 Mil. Therefore, Nanosonics's EBITDA margin for the quarter that ended in Dec. 2025 was 15.09%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanosonics EBITDA Margin % Related Terms
Nanosonics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nanosonics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanosonics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a EBITDA Margin % of 15.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanosonics and its competitors. This is near median its historical median of 15.73. Over the past decade, Nanosonics' EBITDA Margin % has ranged from 4.82 to 22.71. According to the industry distribution chart, Nanosonics ranks #275 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 33.7%.
Is Nanosonics' EBITDA Margin % too high?
Nanosonics' current EBITDA Margin % of 15.09% is near median its 10-year median of 15.73. Over the past 10 years, this metric has ranged from a low of 4.82 to a high of 22.71. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Nanosonics' value of 15.09% is 101.9% above this industry median. Based on the distribution chart, Nanosonics ranks #275 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #275 out of 816 companies for EBITDA Margin %. This puts Nanosonics in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Nanosonics' value of 15.09% is 101.9% above this benchmark. Historically, Nanosonics' own EBITDA Margin % has ranged from 4.82 to 22.71 over the past decade. While the company's 10-year median is 15.73 vs. the industry median of 7.48, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current EBITDA Margin % of 15.09% is 101.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current EBITDA Margin % is 15.09%, which is near median its own 10-year median of 15.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.57, compared to a current price of $2.55 — trading 28.6% below its estimated fair value. The current EBITDA Margin % is 15.09%, which is near median its 10-year median of 15.73 and 101.9% above the Medical Devices & Instruments industry median of 7.48. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanosonics (NNCSF), the current EBITDA Margin % is 15.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 28.6% below its estimated GF Value™ of $3.57.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
EBITDA Margin %: 15.09% (near median its 10-year median of 15.73)
GF Value™: $3.57 vs. price of $2.55 (28.6% below fair value)
Industry Position: 101.9% above the Medical Devices & Instruments median (#275 of 816)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
